Macrophage migration inhibitory factor (MIF): A glucocorticoid counter- regulator within the immune system

Critical Reviews in Immunology

Volumn 17, Issue 1, 1997, Pages 77-88

  Calandra, Thierry ^a   Bucala, Richard ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

cytokine; glucocorticoids; macrophage; MIF; pituitary; septic shock; T cell

Indexed keywords

GLUCOCORTICOID; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADENOHYPOPHYSIS; ARTICLE; ENDOTOXEMIA; HORMONAL REGULATION; HUMAN; IMMUNOREGULATION; MACROPHAGE ACTIVATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SEPTIC SHOCK;

EID: 0031015017     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v17.i1.30     Document Type: Article

References (52)

1. Orth, D. N., Kovacs, W. J., and DeBold, C. R., Williams Textbook of Endocrinology, The Adrenal Cortex, 4th ed., Wilson, J. D. and Foster, D. W., Eds., Saunders, Philadelphia, 1992, 489.
2. Goldstein, R. A., Bowen, D. L., and Fauci, A. S., Inflammation: Basic Principles and Clinical Correlates, Adrenal Corticosteroids, 2nd ed., Gallin, J. I., Goldstein, I. M., and Snyderman, R., Eds., Raven Press, New York, 1992, 1061.
3. Munck A., Guyre, P. M., and Holbrook, N. J., Physiological functions of glucocorticoids in stress and their relation to pharmacological actions, Endocrin. Rev., 5, 25, 1984.
4. Bertini, R., Bianch, M., and Ghezzi, P., Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor, J. Exp. Med., 167, 1708, 1988.
5. Zuckerman, S. H., Shellhaas, J., and Butler, L. D., Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis, Eur. J. Immunol., 19, 301, 1989.
6. George, M. and Vaughan, J. H., In vitro cell migration as a model for delayed hypersensitivity, Proc. Soc. Exp. Biol. Med., 111, 514, 1962.
7. Bloom, B. R. and Bennett, B., Mechanism of a reaction in vitro associated with delayed-type hypersensitivity, Science, 153, 80, 1966.
8. David, J., Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction, Proc. Natl. Acad. Sci. U.S.A., 56, 72, 1966.
9. Nathan, C. F., Remold, H. G., and David, J. R., Characterization of a lymphocyte factor which alters macrophage function, J. Exp. Med., 137, 275, 1973.
10. Nathan, C. F., Kamovsky, M. L., and David, J. R., Alterations of macrophage functions by mediators from lymphocytes, J. Exp. Med., 133, 1356, 1971.
11. Churchill, W. H., Piessens, W. F., Sulis, C. A., and David, J. R., Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells, J. Immunol., 115, 781, 1975.
12. Thurman, G. B., Braude, I. A., Gray, P. W., Oldham, R. K., and Stevenson, H. C., MIF-like activity of natural and recombinant human interferon-gamma and their neutralization by monoclonal antibody, J. Immunol., 134, 305, 1985.
13. McInnes, A. and Rennick, D. M., Interleukin 4 induces cultured monocytes/macrophages to form giant multinucleated cells, J. Exp. Med., 167, 598, 1988.
14. Herriott, M. J. and Leu, R. W., Activation of mouse macrophages for migration inhibition and for tumor cytotoxicity is mediated by interferon-gamma priming and triggering by various agents, J. Interferon Res., 7, 165, 1993.
15. Weiser, W. Y., Temple, P. A., Witek-Gianotti, J. S., Remold, H. G., Clark, S. C., and David, J. R., Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor, Proc. Natl. Acad. Sci. U.S.A., 86, 7522, 1989.
16. Weiser, W. Y., Pozzi, L. M., Titus, R. G., and David, J. R., Human recombinant migration inhibitory factor activates human macrophages to kill Leishmania donovani, J. Immunol., 147, 2006, 1991.
17. Weiser, W. Y., Pozzi, L. M., Titus, R. G., and David, J. R., Recombinant human migration inhibitory factor has adjuvant activity, Proc. Natl. Acad. Sci. U.S.A., 89, 8049, 1992.
18. Orme, I. M., Furney, S. K., Skinner, P. S., et al., Inhibition of growth of Mycobacterium aviun in murine and human mononuclear phagocytes by migration inhibitory factor, Infect. Immun., 61, 338, 1993.
19. Cunha, F. Q., Weiser, W. Y., David, J. R., Moss, D. W., Moncada, S., and Liew, F. Y., Recombinant migration inhibitory factor induces nitric oxyde synthase in murine macrophages, J. Immunol., 150, 1908, 1993.
20. Bernhagen, J., Calandra, T., Mitchell, R. A., et al., MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia, Nature, 365, 756, 1993.
21. Mitchell, R., Bacher, M., Bernhagen, J., Pushkarskaya, T., Seldin, M., and Bucala, R., Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF), J. Immunol., 154, 3863, 1995.
22. Bernhagen, J., Mitchell, R. A., Calandra, T., Voelter, W., Cerami, A., and Bucala, R., Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF), Biochemistry, 33, 14144, 1994.
23. Paralkar, V. and Wistow, G., Cloning the human gene for macrophage migration inhibitory factor (MIF), Genomics, 1948, 1994.
24. Kozak, C. A., Adamson, M. C., Buckler, C. E., Segovia, L., Paralkar, V., and Wistow, G., Genomic cloning of mouse MIF (macrophage inhibitory factor) and genetic mapping of the human and mouse expressed gene and nine mouse pseudogenes, Genomics, 27, 405, 1995.
25. Galat, A., Riviere, S., and Bouet, F., Purification of macrophage migration inhibitory factor (MIF) from bovine brain cytosol, FEBS Lett., 319, 233, 1993.
26. Wistow, G. J., Shaughnessy, M. P., Lee, D. C., Hodin, J., and Zelenka, P. S., A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens, Proc. Natl. Acad. Sci. U.S.A., 90, 1272, 1993.
27. Odh, G., Hindemith, A., Rosengren, A. M., Rosengren, E., and Rorsman, H., Isolation of a new tautomerase monitored by the conversion of d-dopachrome to 5,6-dihydroxyindole, Biochem. Biophys. Res. Commun., 197, 619, 1993.
28. Rosengren, E., Bucala, R., Åman, P., et al., The immunoregulatory mediator macrophage migration inhibitory factor (MIF) calalyzes a tautomerization reaction, Mol. Med., 2, 143, 1996.
29. Sherry, B., Yarlett, N., Strupp, A., and Cerami, A., Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages, Proc. Natl. Acad. Sci. U.S.A., 89, 3511, 1992.
30. Schreiber, S. L. and Crabtree, G. R., The mechanism of action of cyclosporin A and FK506, Immunol. Today, 13, 136, 1992.
31. Lanahan, A., Williams, J. B., Sanders, L. K., and Nathans, D., Growth factor-induced delayed early response genes, Mol. Cell. Biol., 12, 3919, 1993.
32. Sun, H. W., Bernhagen, J., Bucala, R., and Lolis, E., Crystal structure at 2.6 Å resolution of human macrophage migration inhibitory factor, Proc. Natl. Acad. Sci. U.S.A., 93, 5191, 1996.
33. Nishino, T., Bernhagen, J., Shiiki, H., Calandra, T., Dohi, K., and Bucala, R., Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland, Mol. Med., 1, 781, 1995.
34. Thomer, M. O., Vance, M. L., Horvath, E, et al., Williams Textbook of Endocronology, The Anterior Pituitary, Wilson, J. D. and Foster, D. W., Eds., 8th ed., Saunders, Philadelphia, 1992, 221.
35. Frantz, A. G. and Wilson, J. D., Williams Textbook of Endocrinology, Endocrine Disorders of the Breast, Wilson, J. D. and Foster, D. W., Eds., 8th ed., Saunders, Philadelphia, 1992, 953.
36. Calandra, T., Bernhagen, J., Metz, C. N., et al., MIF as a glucocorticoid-induced modulator of cytokine production, Nature, 377, 68, 1995.
37. Calandra, T., Bernhagen, J., Mitchell, R. A., and Bucala R., The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor, J. Exp. Med., 179, 1895, 1994.
38. Metcalf J. A., Gallin, J. I., Nauseef, W. M., et al., Eds., Laboratory Manual of Neutrophil Function, Raven Press, New York, 1986.
39. Cannon, J. G., Tatro, J. B., Reichlin, S., and Dinarello, C. A., α melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of interleukin 1, J. Immunol., 137, 2232, 1986.
40. Bacher, M., Metz, C. N., Calandra, T., et al., An essential regulatory role for MIF in T cell activation, Proc. Natl. Acad. Sci. U.S.A., 93, 5191, 1996.
41. Bernhagen, J., Bacher, M., Calandra, T., et al., An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction, J. Exp. Med., 183, 277, 1996.
42. Tracey, K. J., Beutler, B., Lowry, S. F., Shock and tissue injury induced by recombinant human cachectin, Science, 234, 470, 1986.
43. Okusawa, S., Gelfand, J. A., Ikejima, T., Connolly, R. J., and Dinarello, C. A., Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition, J. Clin. Invest., 81, 1162, 1988.
44. Gillis, S., Crabtree, G. R., and Smith, K. A., Glucocorticoid-induced inhibition of T cell growth factor production, J. Immunol., 123, 1624, 1979.
45. Arya, S. K., Wong-Staal, F., and Gallo, R. C., Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA, J. Immunol., 133, 273, 1984.
46. Knudsen, P. J., Dinarello, C. A., and Strom, T. B., Glucocorticoids inhibit transcriptional and posttranscriptional expression of interleukin-1 in U937 cells, J. Immunol., 139, 4129, 1987.
47. Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., and Cerami, A., Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance, Science, 232, 977, 1986.
48. Lew, W., Oppenheim, J. J., and Matsushima, K., Analysis of the suppression of IL-α and IL-1β production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone, J. Immunol., 140, 1895, 1988.
49. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., and Karin, M., Immunosuppression by glucocorticoids; inhibition of NF-κB activity through induction of IκB synthesis, Science, 270, 286, 1995.
50. Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., and Baldwin, A. S., Jr., Role of transcriptional activation of IκBα mediation of immunosuppression by glucocorticoids, Science, 270, 283, 1995.
51. Bone, R. C., Fisher, C. J., Clemmer, T. P., et al., A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock, N. Engl. J. Med., 317, 653, 1987.
52. The Veterans Administration Systemic Sepsis Cooperative Study Group, Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis, N. Engl. J. Med., 317, 659, 1987.